LncRNA HCG18 promotes prostate cancer progression by regulating the miR-512-3p/HK-2 axis  

作　　者：Yaru Zhu Zhijing Wang Haopeng Li Zhen Ren Tong Zi Xin Qin Wenhuizi Sun Xi Chen Gang Wu 

机构地区：[1]Department of Urology,Tongji Hospital,School of Medicine,Tongji University,Shanghai,China [2]Department of Gastroenterology and Hepatology,Tongji Hospital,School of Medicine,Tongji University,Shanghai,China [3]Department of Medicine,Dalian University of Technology,Dalian,China [4]Department of Obstetrics and Gynecology,Tongji Hospital,School of Medicine,Tongji University,Shanghai,China

出　　处：《Asian Journal of Urology》2024年第4期575-585,共11页亚洲泌尿外科杂志（英文）

基　　金：supported by National Natural Science Foundation of China(81672526 and 81802560 to Wu G);Special Program for Clinical Research of Shanghai Municipal Health Commission(20184Y0263 and 20184Y0105 to Wu G).

摘　　要：Objective:Long non-coding RNAs(lncRNAs)play an important role in tumor progression.Numerous studies show that lncRNAs are strongly associated with prostate cancer(PCa)progression.The aim of this study was to investigate the pathway through which lncRNA HCG18 regulates PCa progression by bioinformatics analysis and experiments.Methods:We compared HCG18 expression in PCa versus normal tissue and cells by data and cell lines,followed by comparing the changes in tumor cell proliferation,migration,and invasive ability after knockdown of HCG18.Then we searched for its downstream pathway by database and validated the pathway in vivo and in vitro.Results:HCG18 was highly expressed in PCa and has the ability to promote tumor proliferation,migration,and invasion;knockdown of HCG18 led to a decrease in the ability of cells to do so,which can be reversed by knockdown of miR-512-3p or overexpression of hexokinase 2.Conclusion:Our in vivo and in vitro experiments suggest that HCG18 can play a role in promoting PCa progression by blocking the inhibition of hexokinase 2 by miR-512-3p via sponge adsorption.

关 键 词：Prostate cancer Long non-coding RNA MicroRNA Hexokinase-2 Warburg effect GLYCOLYSIS 

分 类 号：R737.25[医药卫生—肿瘤]